In our “HOT STOCK” column today, Raymond Chan, Head of Asian Desk, gives us a rundown on what tariffs apply to various pharma stocks and which pharma he sees as an ADD to an investor’s portfolio..

The outlook for CSL (one of the few true global leaders on the ASX) from the analysts (who aren’t always right) is that the recent price decline gives investors an improved access point to a high-qu..

So far so good with the Trump U-turn on tariffs, but uncertainty still prevails. Is cautious buying to take advantage of lower valuations therefore warranted?

In our “HOT” stock article today, Michael Gable, MD of Fairmont Equities, says that for investors still looking to stick with trending stocks, then you can’t go past gold companies, and current ..

In our “HOT STOCK” column today, Raymond Chan, Head of Asian Desk, comments on the position of CSL with regards to the impact of the Trump imposed tariffs.

Beyond tariffs, I think there’s one part of the Trump Administration’s rhetoric that rewards a bit of exploration down in micro-cap world.

With Trump tariffs at this stage slugging Chinese goods with a 34% tariff, here are two exchange traded funds for investors wanting a sensible exposure to China

In our “HOT” stock article today, Michael Gable, MD of Fairmont Equities, says that Macquarie Group (MQG) is a buying opportunity right now.

In our “HOT STOCK” column today, Raymond Chan, Head of Asian Desk, explains that Macquarie Group Ltd (MQG) continues to emphasise its strong long-term structural growth potential.

Here’s a look at three situations that look capable of producing good earnings growth this year – but there still looks to be value in the share price.